Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from QIAGEN

Stocks With Rising Relative Strength: Qiagen

Qiagen shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Qiagen Earns RS Rating Upgrade

Qiagen shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

3 Unusually Active Call Options to Buy With Just 5% Down

Investors continue to wonder how long stocks will keep moving higher. Friday’s jobs report suggests the economy is much stronger than most people realize, which is good news for stocks.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Medical Research Stocks to Buy This Week

With the increased demand for innovative medical products and services, the medical research industry is poised for robust growth. Therefore, three medical research stocks Laboratory Corporation of America (LH), Qiagen N.V. (QGEN), and Lantheus Holdings (LNTH) could be solid buys for this week. Keep reading….

StockNews.com

Why Bio-Rad Laboratories' Rumored $10 Billion Qiagen Buyout Looks Unlikely

A rumored matchup between Bio-Rad Laboratories and Qiagen is unlikely, an analyst said Tuesday as BIO stock fell for a second straight day.

Investors Business Daily

Twitter May Drop Clickable Hashtags, AstraZeneca's Nasal COVID-19 Vaccine Fails Trial, Coinbase Gets Singapore Nod: Top Stories Tuesday, Oct. 11

Reuters US-China Chip War: KLA Relaxes Chip Supply To China

Benzinga

Qiagen Posts Upbeat Q1 Earnings, Raises FY22 Outlook

Qiagen N.V. (NYSE:QGEN) clocked Q1 FY22 revenues of $628.4 million, +11% Y/Y, ahead of the outlook for at least 7% CER growth and well above the consensus of $517.8 million. At constant exchange rates (CER), Q1 revenues jumped 15% Y/Y. Sales were driven by 14% CER growth in the non-COVID-19 product portfolio…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Illumina vs. Qiagen: Which Diagnostics & Research Stock is a Better Buy?

The diagnostics and research industry has grown substantially over the past few years with the integration of advanced technologies and impressive breakthroughs in the early diagnosis of chronic diseases. Given the growing investments in this industry, prominent companies Illumina (ILMN) and Qiagen (QGEN) are well-positioned to benefit. Let’s find out…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.